Cytoo appoints CEO for new US unit
This article was originally published in Clinica
Executive Summary
French developer of high-content cell analysis technologies Cytoo has appointed William Sharp president and CEO of its newly-established US subsidiary. Mr Sharp, who was most recently president and CEO of stem cell technologies company ArunA Biomedical, brings 30 years' experience of marketing life science products and diagnostics to Cytoo's Framingham, Massachusetts-based division. He will oversee opportunities for the company's expansion in North America, and seek to create co-distribution and partnership agreements with leading players in cell-based assays for the drug discovery market. Market data indicate that worldwide sales of cell-based assays reached $1.7bn in 2007, according to Grenoble-headquartered Cytoo.